Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E, Opsomer M, De Meyer S; AMBER and EMERALD Study Groups. Lathouwers E, et al. Among authors: ghys a. AIDS Res Hum Retroviruses. 2020 Jan;36(1):48-57. doi: 10.1089/AID.2019.0111. Epub 2019 Oct 21. AIDS Res Hum Retroviruses. 2020. PMID: 31516033 Free PMC article. Clinical Trial.
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Lathouwers E, Weinsteiger S, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E, De Meyer S. Lathouwers E, et al. Among authors: ghys a. J Med Virol. 2021 Jun;93(6):3985-3990. doi: 10.1002/jmv.26721. Epub 2021 Feb 15. J Med Virol. 2021. PMID: 33300183 Clinical Trial.
Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study.
Dierynck I, Thys K, Ghys A, Sullivan JC, Kieffer TL, Aerssens J, Picchio G, De Meyer S. Dierynck I, et al. Among authors: ghys a. J Infect Dis. 2014 Dec 15;210(12):1871-80. doi: 10.1093/infdis/jiu340. Epub 2014 Jun 18. J Infect Dis. 2014. PMID: 24943725 Clinical Trial.
Modeling viral evolutionary dynamics after telaprevir-based treatment.
Haseltine EL, De Meyer S, Dierynck I, Bartels DJ, Ghys A, Davis A, Zhang EZ, Tigges AM, Spanks J, Picchio G, Kieffer TL, Sullivan JC. Haseltine EL, et al. Among authors: ghys a. PLoS Comput Biol. 2014 Aug 7;10(8):e1003772. doi: 10.1371/journal.pcbi.1003772. eCollection 2014 Aug. PLoS Comput Biol. 2014. PMID: 25101970 Free PMC article.
46 results